{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:42:58Z","timestamp":1787866978974,"version":"build-2784847793"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Canada Inc. Medical"},{"name":"Ruth Moulson of Pentavere Research Group"},{"DOI":"10.13039\/100016040","name":"Takeda Canada Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>This study explores the effectiveness of vedolizumab dose escalation among patients with ulcerative colitis or Crohn\u2019s disease who experienced a suboptimal or loss of clinical response in a Canadian real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderately to severely active ulcerative colitis or Crohn\u2019s disease treated with vedolizumab were prospectively followed in a patient support program in Canada from 2015 to 2023. In patients who dose escalated to every 4\u2009weeks from every 8\u2009weeks intravenous maintenance dosing, Harvey-Bradshaw Index and Partial Mayo Scores were assessed 12 and 52\u2009weeks after dose escalation. Clinical remission was defined as Harvey-Bradshaw Index &amp;lt; 5 or Partial Mayo Score &amp;lt; 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 924 patients with Crohn\u2019s disease (45% bio-na\u00efve) and 1816 patients with ulcerative colitis (71% bio-na\u00efve). Of patients with Crohn\u2019s disease, 39% bio-na\u00efve and 54% bio-experienced dose-escalated within the first 2 years. Of patients with ulcerative colitis, 39% bio-na\u00efve and 50% bio-experienced dose escalated within the first 2 years. For Crohn\u2019s disease patients receiving every 8 weekly intravenous maintenance dosing who were not in clinical remission, 50% bio-na\u00efve and 23% bio-experienced patients were in clinical remission 12\u2009weeks after dose escalation, while for ulcerative colitis, 43% bio-na\u00efve and 35% bio-experienced patients were in clinical remission 12\u2009weeks after dose escalation, which was sustained through 52\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients who experienced a suboptimal or loss of clinical response to vedolizumab, this study supports the real-world effectiveness of intravenous vedolizumab dose escalation in improving clinical response and clinical remission rates among patients with ulcerative colitis or Crohn\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jcag\/gwaf033","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:13:18Z","timestamp":1764335598000},"page":"30-37","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of vedolizumab dose escalation in inflammatory bowel disease in a large-scale, Canadian real-world cohort"],"prefix":"10.1093","volume":"9","author":[{"given":"Edmond-Jean","family":"Bernard","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al Department of Gastroenterology, , Montr\u00e9al, QC, H3T 1J4,","place":["Canada"]},{"name":"CHUM Department of Gastroenterology, , Montr\u00e9al, QC, H2X 0C1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8477-6337","authenticated-orcid":false,"given":"Jean-Frederic","family":"Leblanc","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al Department of Gastroenterology, , Montr\u00e9al, QC, H3T 1J4,","place":["Canada"]},{"name":"Sacre-Coeur Hospital Department of Medicine, , Montreal, QC, H4J 1C5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"University of Toronto Department of Medicine, , Toronto, ON, M5S 3H2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Takeda Canada Inc Gastroenterology, , Toronto, ON, M5H 4E3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-0839","authenticated-orcid":false,"given":"Marie-Julie","family":"Allard","sequence":"additional","affiliation":[{"name":"Takeda Canada Inc Gastroenterology, , Toronto, ON, M5H 4E3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ward","sequence":"additional","affiliation":[{"name":"Takeda Canada Inc Gastroenterology, , Toronto, ON, M5H 4E3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weiss","sequence":"additional","affiliation":[{"name":"Pentavere Research Group Inc Clinical Department, , Toronto, ON, M6G 1A1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pettengell","sequence":"additional","affiliation":[{"name":"Pentavere Research Group Inc Clinical Department, , Toronto, ON, M6G 1A1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-8209","authenticated-orcid":false,"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[{"name":"University of British Columbia Division of Gastroenterology, , Vancouver, BC, V6T 1Z7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026020910515514300_gwaf033-B1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2026020910515514300_gwaf033-B2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2026020910515514300_gwaf033-B3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026020910515514300_gwaf033-B4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.crohns.2012.01.019","article-title":"Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNF\u03b1 treatment","volume":"6","author":"Casellas","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2026020910515514300_gwaf033-B5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/14656566.2016.1187132","article-title":"Maintenance therapy options for ulcerative colitis","volume":"17","author":"Chaparro","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"2026020910515514300_gwaf033-B6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2026020910515514300_gwaf033-B7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jaut.2017.07.004","article-title":"Novel therapeutic targets for inflammatory bowel disease","volume":"85","author":"Argollo","year":"2017","journal-title":"J Autoimmun"},{"key":"2026020910515514300_gwaf033-B8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sw","year":"2024","journal-title":"N Engl J Med"},{"key":"2026020910515514300_gwaf033-B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Fb","year":"2024","journal-title":"N Engl J Med"},{"key":"2026020910515514300_gwaf033-B10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of clinical response to vedolizumab and ability of dose intensification to restore clinical response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026020910515514300_gwaf033-B11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.18553\/jmcp.2020.19388","article-title":"Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease","volume":"26","author":"Ehrenberg","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2026020910515514300_gwaf033-B12","doi-asserted-by":"publisher","first-page":"S524","DOI":"10.1093\/ecco-jcc\/jjz203.760","article-title":"P632 vedolizumab dose escalation in patients with inflammatory bowel disease experiencing loss of clinical response: a systematic review and meta-analysis of real-world evidence","volume":"14","author":"Varghese","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026020910515514300_gwaf033-B13","doi-asserted-by":"publisher","first-page":"otac020","DOI":"10.1093\/crocol\/otac020","article-title":"Real-world effectiveness of vedolizumab dose escalation in patients with inflammatory bowel disease: a systematic literature review","volume":"4","author":"Patel","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026020910515514300_gwaf033-B14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/03007995.2017.1335001","article-title":"Dose escalation of biologics in Crohn\u2019s disease: critical review of observational studies","volume":"33","author":"Einarson","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2026020910515514300_gwaf033-B15","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1080\/03007995.2019.1631058","article-title":"Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence","volume":"35","author":"Gemayel","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026020910515514300_gwaf033-B16","author":"Takeda Canada Inc","year":"2023"},{"key":"2026020910515514300_gwaf033-B17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"2026020910515514300_gwaf033-B18","author":"Alimentiv Inc. (Sponsor)","year":"2024"},{"key":"2026020910515514300_gwaf033-B19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jcag\/gwae010","article-title":"The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study","volume":"7","author":"Seow","year":"2024","journal-title":"J Can Assoc Gastroenterol"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/9\/1\/30\/65823042\/gwaf033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/9\/1\/30\/65823042\/gwaf033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:52:03Z","timestamp":1770652323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/9\/1\/30\/8375617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwaf033","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,9]]}}}